Filing Flows › TriSalus Life Sciences (TLSI) › R&D spending
TriSalus Life Sciences (TLSI) R&D spending by quarter
TriSalus Life Sciences' R&D spending was $3.1M in Q2 2026 (second quarter 2026), -2% from Q1 2026. Over the last 6 quarters it ranged from $2.6M (Q4 2025) to $5.2M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $3.1M | -2% | — |
| Q1 2026 | $3.2M | +25% | -2% |
| Q4 2025 | $2.6M | -50% | -13% |
| Q3 2025 | $5.2M | +57% | — |
| Q1 2025 | $3.3M | +11% | — |
| Q4 2024 | $3.0M | — | — |
Q2 2026 at a glance
TriSalus Life Sciences, Q2 2026: revenue $11.4M (+2% year over year), operating margin -86.0%, net loss $9.2M, operating cash flow −$10.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is TriSalus Life Sciences' R&D spending?
TriSalus Life Sciences' R&D spending was $3.1M in Q2 2026 (second quarter 2026), -2% from Q1 2026.
How has TriSalus Life Sciences' R&D spending changed?
Over the last 6 quarters it ranged from $2.6M (Q4 2025) to $5.2M (Q3 2025).
Q2 2026 results → · How TriSalus Life Sciences makes money →